# NCT05327530 (NCT05327530)

> A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05327530
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Conditions: Locally Advanced or Metastatic Urothelial Carcinoma
- Interventions: Avelumab; Sacituzumab Govitecan (SG); M6223; NKTR-255; JB100
- Enrollment: 256
- Primary outcome: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + Sacituzumab Govitecan Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])
- Primary outcome: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + M6223 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])
- Primary outcome: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + NKTR-255 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])
- Primary outcome: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events, and AEs of Special Interest (AESIs)

## Commentary we found

- X threads: 15
- Podcasts: 3
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct05327530

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05327530", "email": "<work email>"}; the inbox owner confirms by the emailed link.